Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results
, , , , , , , und
22. Feb. 2017
Über diesen Artikel
Artikel-Kategorie: Research Article
Online veröffentlicht: 22. Feb. 2017
Seitenbereich: 74 - 80
Eingereicht: 23. Dez. 2016
Akzeptiert: 12. Jan. 2017
DOI: https://doi.org/10.1515/raon-2017-0007
Schlüsselwörter
© 2017 Lawrence Bonne, Chris Verslype, Annouschka Laenen, Sandra Cornelissen, Christophe M. Deroose, Hans Prenen, Vincent Vandecaveye, Eric Van Cutsem, Geert Maleux
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Procedure-related toxicity
Ischemic cholecystits | 3 | 1 | 6 |
Carcinoid storm | 2 | 1 | 6 |
Insulin storm | 2 | 1 | 6 |
Postembolization syndrome 2 | 14 | 82 |
Patients’ demographic data
Age (years) | |
Mean | 56 |
SD | 13.9 |
Range | 18–82 |
Sex | |
M | 8 |
F | 9 |
Primary tumour | |
Intestinal NET | 6 |
Pancreatic NET | 2 |
Pulmonary NET | 2 |
Pancreatic insulinoma | 4 |
Unknown | 3 |
Surgical resection of primary tumour | |
Intestinal NET | 5 |
Pancreatic NET | 2 |
Pulmonary NET | 2 |
Pancreatic insulinoma | 1 |
Total | 10 |
Tumour grade (Ki-67 index) | |
Ki-67 < 2% | 4 |
Ki-67 2–20% | 6 |
Ki-67 > 20% | 4 |
Unknown | 3 |
Tumour burden (% of total liver volume) | |
0–10% | 4 |
10–20% | 3 |
20–50% | 5 |
> 50% | 5 |
Extrahepatic metastatic disease | 16 |
Lymphadenopathy | 7 |
Bone | 5 |
Lung | 3 |
Spleen | 1 |
Adrenal | 3 |
Brain | 1 |
Ovary | 2 |
Pancreas | 2 |
Peritoneum | 1 |
Skin | 1 |
Previous treatment | |
Surgical resection of liver metastases | 1 |
Radiofrequency ablation of liver metastases | 1 |
Radiotherapy for brain metastases | 1 |
Radiotherapy for bone metastases | 1 |
Interferon | 3 |
Everolimus | 7 |
m-TOR-inhibitor | 1 |
Sunitinib | 4 |
Somatostatine analogue | 15 |
Diazoxide | 3 |